A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Actinic Keratosis
Interventions
DRUG

Lesion count

Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.

Trial Locations (17)

23507

Virginia Clinical Research, Inc, Norfolk

24501

The Education and Research Foundation, Lynchburg

30022

Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta

45220

Group Health Associates, Cincinnati

46256

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

47713

Deaconess Clinic Downtown, Evansville

60005

Altman Dermatology Associates, Arlington Heights

60089

Glazer Dermatology, Buffalo Grove

68144

Skin Specialists, PC, Omaha

71913

Burke Pharmaceutical Research, Hot Springs

75703

Dermatology Associates of Tyler, Tyler

77056

Suzanne Bruce and Associates, PA, The Center for Skin Research, Houston

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

78759

DermResearch, Inc., Austin

84124

Dermatology Research Centre, Salt Lake City

89002

Karl G. Heine Dermatology, Henderson

92117

Skin Surgery Medical Group Inc., San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00989313 - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study | Biotech Hunter | Biotech Hunter